Becton, Dickinson and Company BDX Business Segments
| Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | ||
|---|---|---|---|---|---|---|
| Segment Other Operating Expense (Income), net as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 0%— | 0%— | —— | —— | 0%— | |
| Connected Care | 0.3%+0.1pp | 0.3%-0.3pp | —— | —— | 0.2%— | |
| Interventional | 0%— | 0%— | —— | —— | 0%— | |
| Medical Essentials | 0%— | 0%— | —— | —— | 0%— | |
| Revenue by Business | ||||||
| BioPharma Systems | $590M+2.6% | $429M+2.6% | —— | —— | $575M— | |
| Connected Care | $1.12B+4.9% | $1.13B+5.4% | —— | —— | $1.07B— | |
| Interventional | $1.36B+7.4% | $1.33B+5.8% | $1.37B+8.6% | $1.33B+7.1% | $1.26B-2.2% | |
| Medical Essentials | $1.65B+4.7% | $1.6B+0.6% | —— | —— | $1.57B— | |
| Other Operating Income by Business | ||||||
| BioPharma Systems | $0— | $0— | —— | —— | $0— | |
| Connected Care | -$3M-50.0% | -$3M+50.0% | —— | —— | -$2M— | |
| Interventional | $0— | $0— | —— | —— | $0— | |
| Medical Essentials | $0— | $0— | —— | —— | $0— | |
| Segment Selling and Administrative as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 5.4%+0.6pp | 6.6%-0.2pp | —— | —— | 4.8%— | |
| Connected Care | 17%+1.9pp | 16.9%+1.2pp | —— | —— | 15.1%— | |
| Interventional | 20.4%+1.8pp | 19.7%+0.8pp | —— | —— | 18.6%+13.9pp | |
| Medical Essentials | 11.2%+0.8pp | 11.3%+0.9pp | —— | —— | 10.4%— | |
| Operating Income (Loss) by Business | ||||||
| BioPharma Systems | $225M+0.4% | $140M-0.7% | —— | —— | $224M— | |
| Connected Care | $347M-1.7% | $352M+4.8% | —— | —— | $353M— | |
| Interventional | $579M+2.5% | $561M0.0% | —— | —— | $565M+6.9% | |
| Medical Essentials | $574M-7.0% | $569M-6.3% | —— | —— | $617M— | |
| Segment Cost of Products and Services Sold as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 53.6%+0.4pp | 56.6%+1.2pp | —— | —— | 53.2%— | |
| Connected Care | 43.7%-1.1pp | 44.3%-0.7pp | —— | —— | 44.8%— | |
| Interventional | 31.6%-0.1pp | 33.5%+1.4pp | —— | —— | 31.7%+23.2pp | |
| Medical Essentials | 50.7%+3.7pp | 50.1%+1.6pp | —— | —— | 47%— | |
| Segment Research and Development as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 2.8%-0.3pp | 4.1%0.0pp | —— | —— | 3.1%— | |
| Connected Care | 8.1%+1.2pp | 7.5%+0.1pp | —— | —— | 6.9%— | |
| Interventional | 5.3%+0.3pp | 4.7%+0.3pp | —— | —— | 5%+3.9pp | |
| Medical Essentials | 3.2%+0.1pp | 2.9%+0.1pp | —— | —— | 3.1%— | |
| Segment Operating Income (Loss) as a Percent of Revenues by Business | ||||||
| BioPharma Systems | 38.1%-0.8pp | 32.6%-1.1pp | —— | —— | 38.9%— | |
| Connected Care | 31%-2.0pp | 31.1%-0.2pp | —— | —— | 33%— | |
| Interventional | 42.7%-2.0pp | 42.1%-2.5pp | —— | —— | 44.7%+34.1pp | |
| Medical Essentials | 34.8%-4.5pp | 35.6%-2.7pp | —— | —— | 39.3%— | |
| Selling and administrative expense by Business | ||||||
| BioPharma Systems | $32M+14.3% | $29M0.0% | —— | —— | $28M— | |
| Connected Care | $190M+18.0% | $191M+13.7% | —— | —— | $161M— | |
| Interventional | $277M+17.4% | $262M+10.5% | —— | —— | $236M-0.1% | |
| Medical Essentials | $185M+12.8% | $180M+9.1% | —— | —— | $164M— | |
| Cost of products sold by Business | ||||||
| BioPharma Systems | $316M+3.3% | $243M+4.7% | —— | —— | $306M— | |
| Connected Care | $490M+2.5% | $501M+3.7% | —— | —— | $478M— | |
| Interventional | $429M+7.0% | $445M+10.1% | —— | —— | $401M-5.3% | |
| Medical Essentials | $835M+12.4% | $800M+3.9% | —— | —— | $743M— | |
| Research and development expense by Business | ||||||
| BioPharma Systems | $17M-5.6% | $18M+5.9% | —— | —— | $18M— | |
| Connected Care | $90M+21.6% | $85M+6.3% | —— | —— | $74M— | |
| Interventional | $72M+14.3% | $63M+12.5% | —— | —— | $63M+11.5% | |
| Medical Essentials | $53M+10.4% | $47M+6.8% | —— | —— | $48M— | |
| D&A by Business | ||||||
| BioPharma Systems | $27M-15.6% | $34M+9.7% | —— | —— | $32M— | |
| Connected Care | $194M-2.5% | $194M0.0% | —— | —— | $199M— | |
| Interventional | $192M-3.0% | $197M-1.5% | —— | —— | $198M+0.8% | |
| Medical Essentials | $147M+8.1% | $141M+4.4% | —— | —— | $136M— | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| BioPharma Systems | $0— | $0— | —— | —— | —— | |
| Connected Care | -$1M— | -$1M— | —— | —— | —— | |
| Interventional | $13M+154% | -$3M-105% | -$8M+83.3% | -$69M— | -$24M— | |
| Medical Essentials | $6M— | -$4M— | —— | —— | —— | |
| Goodwill by Business | ||||||
| BioPharma Systems | $96M— | $96M— | $96M— | —— | —— | |
| Connected Care | $6.1B— | $6.09B— | $6.09B— | —— | —— | |
| Interventional | $12.76B+0.5% | $12.77B+0.8% | $12.76B+0.3% | $12.76B+0.6% | $12.69B0.0% | |
| Medical Essentials | $7.01B— | $7.02B— | $7.01B— | —— | —— | |
| Revenue, remaining performance obligation, amount by Product | ||||||
| Consumables | $2B-9.1% | $2.4B+20.0% | $2.3B+9.5% | $2.3B+9.5% | $2.2B+4.8% | |
| Products and/or Services | $2.3B-4.2% | $2.5B+8.7% | $2.8B+21.7% | $2.5B+8.7% | $2.4B+4.3% | |
| Revenue by Geography | ||||||
| International | $1.8B+5.5% | $2.09B+0.2% | $2.47B+6.4% | $2.33B+11.0% | $1.7B-20.3% | |
| UNITED STATES | $2.92B+5.1% | $3.16B+2.6% | $3.42B+9.8% | $3.18B+10.0% | $2.78B-4.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Becton, Dickinson and Company break its business down?
- Becton, Dickinson and Company (BDX) reports segment other operating expense (income), net as a percent of revenues by business across 5 parts — BioPharma Systems, Connected Care, Interventional, Medical Essentials and Medical. Each is extracted from the segment footnotes and tracked over time.
- Where does Becton, Dickinson and Company's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Becton, Dickinson and Company's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
